Effect of daclizumab on inflammatory infiltrate in fine needle aspiration biopsy in patients after liver transplantation.
OBJECTIVE
FNAB is a cytological procedure enabling the monitoring of inflammatory cells in the graft, morphological modification of parenchymal cells, and expression of antigens on aspirated cells. The aim of the study was to evaluate whether Daclizumab influences the composition of inflammatory infiltrate and expression of HLA-DR antigens and intercellular adhesive molecule ICAM-1 on parenchymal cells.


METHODS
Two groups of liver allograft recipients were included and they were treated with two different immunosuppressive protocols. The first group with quadruple immunosuppression therapy (Cyclosporine A, Mycophenolate mofetil, steroids, and Daclizumab). The second group with quadruple combination immunosuppression (Cyclosporine A, Azathioprine, steroids and ATG-Fresenius). FNAB and blood samples were collected simultaneously. Corrected increments of inflammatory cells were statistically evaluated as well as expression of HLA-DR antigens and ICAM-1 on parenchymal cells.


RESULTS
FNAB specimens from the Daclizumab group demonstrated significantly lower values of the total corrected increment, the corrected increment of monocytes, number of blast cells per slide, and a lower number of ICAM-1 expressing parenchymal cells.


CONCLUSIONS
We summarise that Daclizumab significantly reduces inflammatory cells in liver graft, as well as expression of ICAM-1 on parenchymal cells.
Lodererová
A
A
Institute for Clinical and Experimental Medicine, Prague, Czech Republic, Department of Pathology, Department of Hepatogastroenterology, Transplantcenter. a.lodererova@volny.cz
Trunecka
P
P
Honsová
E
E
Wohl
P
P
Vítko
S
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001707:Biopsy, Needle; D000077561:Daclizumab; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007958:Leukocyte Count; D016031:Liver Transplantation / Q000276:immunology / Q000473:pathology*; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006684:HLA-DR Antigens; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab